675 McDonnell Boulevard
About Mallinckrodt PharmaceuticalsMallinckrodt is a global business that develops, manufactures, markets and distributes specialty pharmaceutical and biopharmaceutical products and therapies, as well as nuclear imaging products. Areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and hemostasis products; and central nervous system drugs.
Founder: Emil Mallinckrodt
CEO: Mark Trudeau
CFO: Matthew Harbaugh
Please click here for Mallinckrodt job opportunities.
303 articles with Mallinckrodt Pharmaceuticals
Mallinckrodt Announces Positive Top-Line Results from its Pivotal Phase 3 CONFIRM Trial of Terlipressin in Patients with Hepatorenal Syndrome Type 1 (HRS-1)
Mallinckrodt plc announced positive top-line results from its pivotal Phase 3 CONFIRM clinical study evaluating the efficacy and safety of terlipressin in 300 adults with hepatorenal syndrome type 1.
8/15/2019Mallinckrodt’s experimental drug terlipressin hit the mark in a late-stage liver disease trial. Mallinckrodt said terlipressin met its primary endpoint in reversing three components of hepatorenal syndrome type 1.
Mallinckrodt Announces Publication of Results of Phase 1b Clinical Trial of StrataGraft® Regenerative Tissue in Burns
Mallinckrodt plc announced publication of results of its Phase 1b clinical trial of StrataGraft®, an investigational regenerative tissue, in Burns, the journal of the International Society for Burn Injuries.
First Patient Enrolled in Mallinckrodt's Phase 2a Study of Investigational Drug MNK-6106 in Hepatic Cirrhosis and Chronic Hepatic Encephalopathy (HE)
Trial is to Assess Pharmacokinetics, Pharmacodynamics and Safety of the Oral Administration of MNK-6106 in Patients with HE
Mallinckrodt plc Reports Strong Results in Second Quarter 2019, Raises Adjusted EPS Guidance for 2019, and Announces Suspension of Specialty Generics Spin-off
Mallinckrodt plc, a global biopharmaceutical company, reported results for the three months ended June 28, 2019.
8/6/2019Mallinckrodt said it remains committed to becoming an “innovation-driven specialty brands business.”
Mallinckrodt Pharmaceuticals, a global biopharmaceutical company, will present on Thursday, Sept. 5, 2019, at the Wells Fargo Securities 2019 Healthcare Conference at the Westin Copley Place, 10 Huntington Ave., Boston.
7/22/2019Here's a look at the top clinical trial news from last week, with updates from Neon, GSK, Biohaven, and more.
Mallinckrodt To Make An Equity Investment In Silence Therapeutics As Part Of A Collaboration To Develop And Commercialize RNAi Therapeutics For Complement-Mediated Diseases
Mallinckrodt Chief Scientific Officer Steven Romano, M.D. joins Silence Board as non-executive Director
Mallinckrodt And Silence Therapeutics Announce Collaboration To Develop And Commercialize RNAi Therapeutics For Complement-Mediated Diseases
Collaboration advances Silence's proprietary platform in the growing field of RNAi technology
The companies will develop therapies that target the complement cascade, a group of proteins known to play a role in autoimmune diseases.
7/17/2019A federal judge ordered that information on sales of opioids up to the year 2013 could be released.
A disproportionate number of ALS patients on the investigational drug developed pneumonia.
Mallinckrodt Halts Phase 2B Trial Investigating the Use of Acthar® Gel (Repository Corticotropin Injection) in Amyotrophic Lateral Sclerosis (ALS)
Mallinckrodt plc announced that it is permanently discontinuing its Phase 2B study designed to assess the efficacy and safety of Acthar® Gel as an investigational treatment for amyotrophic lateral sclerosis.
Mallinckrodt plc, a global biopharmaceutical company, announced that it will report second quarter 2019 earnings results for the period ending June 28, 2019 on Tuesday, Aug. 6, 2019.
Mallinckrodt Achieves 50 Percent Enrollment for Phase 2B Trial Investigating the Use of Acthar® Gel (Repository Corticotropin Injection) in Amyotrophic Lateral Sclerosis (ALS)
Mallinckrodt plc, confirmed it has achieved 50 percent patient enrollment in the company's Phase 2B study designed to assess the efficacy and safety of Acthar® Gel as an investigational treatment for amyotrophic lateral sclerosis.
All Primary and Secondary Outcome Targets Met in Mallinckrodt's Phase 4 Acthar® Gel (Repository Corticotropin Injection) Rheumatoid Arthritis (RA) Clinical Trial (n=259) with Data Presented at the European Congress of Rheumatology 2019 (EULAR)
Study met primary outcome measure; 63 percent of patients with persistently active RA achieved low disease activity (LDA) as assessed by DAS28-ESR¹ at Week 12
Mallinckrodt Pharmaceuticals, a global biopharmaceutical company, will present on Tuesday, June 25, 2019, at the BMO Capital Markets 2019 Prescriptions for Success Healthcare Conference at the Mandarin Oriental, 80 Columbus Circle, New York.
Mallinckrodt Pharmaceuticals, a global biopharmaceutical company, will present on Wednesday, June 19, 2019, at the Raymond James Life Sciences and MedTech Conference at the Lotte New York Palace, 455 Madison Ave, New York.
Mallinckrodt Announces Positive Open-Label Results from Phase 4 Acthar® Gel (Repository Corticotropin Injection) Clinical Trial in Rheumatoid Arthritis (RA) to be Presented at the European Congress of Rheumatology 2019 (EULAR)
Mallinckrodt plc, a global specialty biopharmaceutical company, is reporting data1 from the open-label part of the Phase 4, multicenter study assessing the efficacy and safety of Acthar® Gel in patients with persistently active rheumatoid arthritis who were previously treated with disease-modifying anti-rheumatic drugs and corticosteroids.